Evaluation of Tablets 11-21: The Metoprolol succinate tablets were evaluated for weight variation, content uniformity, hardness, friability, swelling index and drug release. The objective of this study was to develop a sustained release matrix tablet Metoprolol Succinate by cost saving and production efficient process. Among various tablet trials were formulated and evaluated using different concentrations of directly compressible s release retardant. The formulated tablets were evaluated for physical and dissolution study using buffer medium. The most outstanding. It is possible to fabricate modified release tablets of metoprolol succinate using hydroxypropyl methylcellulose (Methocel® K100M) and xanthan gum. The combination of matrixing agents namely xanthan gum and Methocel® K100M overcomes disadvantages of each polymer. The initial drug burst release was controlled by quick gelation of xanthan gum whereas subsequent drug release and matrix. Preparation of Metoprolol succinate sustained release matrix layer tablets The nine formulations bearing 50 mg of drug Metoprolol succinate were prepared by wet granulation method. Metoprolol suc- cinate, HPMC K4M, Starch 1500, MCC PH102, Eudragit L1008 were mixed thoroughly in mortar and pestle for 10 minutes to obtain a homogeneous blend. The wet mass was then passed through sieve 16 to. formulation and evaluation of metoprolol succinate controlled release tablets using natural and synthetic polymer html full text. formulation and evaluation of metoprolol succinate controlled release tablets using natural and synthetic polymer matrix tablets of Metoprolol Succinate using Xanthan gum as a carrier. In this context, In this context, studies were reported on the design of three-layer Guar gum matrix tablets for oral Eight batches of ER matrix tablets of Metoprolol succinate were developed by using wet granulation technique and coated with hydroxy propyl methyl cellulose (KM 100) and hydroxyl methyl cellulose for extended release. The present invention relates to modified release pharmaceutical composition comprising metoprolol succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s). More specifically, the invention relates to modified release pharmaceutical compositions comprising metoprolol succinate and a process for. 6 Dissolution Technologies | FEBRUARY 2006 Comparison of Drug Release From Metoprolol Modified Release Dosage Forms in Single Buffer versus a pH-Gradient Dissolution Test Abstract: The aim of the present study was to formulate the Metoprolol Succinate sustained release matrix tablets by cost saving and production efficient process. Among various tablet manufacturing process, direct compression is the.